TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)
Brief Summary: The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters \[ml\]), Aricept (10 miligrams \[mg\]), and a combination of both treatments on cognitive performance and global function in patients with probable Alzheimer's Disease (AD). It should also be assessed if the treatments have a positive effect on activities of daily living and neuropsychiatric symptoms.

Oral treatment with Aricept or Placebo was given once daily throughout the study. Intravenous treatment with Cerebrolysin or Placebo was given once daily for 5 days per week during week 1 to 4 and during week 13 to 16 of the study. During the study patients had six visits at the hospital for evaluation.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Cerebrolysin + donepezil; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + donepezil | Arm Label: Cerebrolysin + placebo; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + placebo | Arm Label: Donepezil + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil + placebo | Intervention Type: DRUG; Name: Cerebrolysin + donepezil; Assigned to Arm(s): Cerebrolysin + donepezil | Intervention Type: DRUG; Name: Cerebrolysin + placebo; Assigned to Arm(s): Cerebrolysin + placebo | Intervention Type: DRUG; Name: Donepezil + placebo; Assigned to Arm(s): Donepezil + placebo
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome
Brief Summary: Identifying a simple dietary recommendation for weight loss and metabolic health may demonstrate potential for a simple public health message to impact coronary heart disease (CHD) prevention and metabolic syndrome. In a randomized clinical trial, the investigators propose to compare the efficacy of two intervention approaches to dietary change for CHD prevention among persons with metabolic syndrome. The two approaches are 1) the AHA Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. The investigators hypothesize that a message promoting high fiber intake may be the simple message that has potential to produce broad impact.


Options:
A: Arm Label: High Fiber Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention | Arm Label: AHA Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Dietary Intervention; Assigned to Arm(s): AHA Diet, High Fiber Diet
B: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Web-based only (WO) weight intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention | Arm Label: WO & peer-led discussion board (WD); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO plus peer-led discussion board (WD) | Arm Label: WO & professional email counseling (WE); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO & professional email counseling (WE) | Intervention Type: BEHAVIORAL; Name: Experimental: Web-based only (WO) weight intervention; Assigned to Arm(s): WO & peer-led discussion board (WD), WO & professional email counseling (WE), Web-based only (WO) weight intervention | Intervention Type: BEHAVIORAL; Name: Experimental: WO plus peer-led discussion board (WD); Assigned to Arm(s): WO & peer-led discussion board (WD) | Intervention Type: BEHAVIORAL; Name: Experimental: WO & professional email counseling (WE); Assigned to Arm(s): WO & professional email counseling (WE)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.
Brief Summary: This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.


Options:
A: Arm Label: BOTOX®; Type: EXPERIMENTAL; Interventions: Biological: BOTOX®, Drug: solifenacin placebo | Arm Label: solifenacin; Type: ACTIVE_COMPARATOR; Interventions: Biological: BOTOX®, Drug: solifenacin, Drug: Botox placebo (normal saline) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: BOTOX®, Drug: Botox placebo (normal saline), Drug: solifenacin placebo | Intervention Type: BIOLOGICAL; Name: BOTOX®; Assigned to Arm(s): BOTOX®, placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): solifenacin | Intervention Type: DRUG; Name: Botox placebo (normal saline); Assigned to Arm(s): placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin placebo; Assigned to Arm(s): BOTOX®, placebo
B: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fesoterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fesoterodine fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fesoterodine fumarate; Assigned to Arm(s): Fesoterodine
D: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Randomised Controlled Study Comparing The Effect of High Cut-off Point Haemofiltration With Standard Haemofiltration In Patients With Acute Renal Failure
Brief Summary: This trial aims to study the effect of combining continuous and a new polyamide membrane with larger pores in the treatment of critically ill patients with acute renal failure and low blood pressure (shock) requiring noradrenaline. The investigators wish to compare the clinical effect of this new therapy to that of haemofiltration with a standard membrane.


Options:
A: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
B: Arm Label: AN69ST; Type: EXPERIMENTAL; Interventions: Device: AN69ST hemofilter | Arm Label: AN69; Type: ACTIVE_COMPARATOR; Interventions: Device: AN69 hemofilter | Intervention Type: DEVICE; Name: AN69ST hemofilter; Assigned to Arm(s): AN69ST | Intervention Type: DEVICE; Name: AN69 hemofilter; Assigned to Arm(s): AN69
C: Arm Label: oXiris; Type: ACTIVE_COMPARATOR; Interventions: Device: oXiris | Arm Label: ST150; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: oXiris; Assigned to Arm(s): oXiris
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: High cut-off (super high flux) polyamide membrane | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard polyamide high flux membrane | Intervention Type: DEVICE; Name: Standard polyamide high flux membrane; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: High cut-off (super high flux) polyamide membrane; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study
Brief Summary: The purpose of this study is to determine the effects of the anticholinesterase drug donepezil on sleep apnea patients. Sleep structure and respiratory parameters will be analyzed by polysomnography.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Donepezil; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): Donepezil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DEVICE; Name: CPAP (Continuous Positive Airway Pressure); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis
Brief Summary: This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.


Options:
A: Arm Label: conventional treatment; Type: EXPERIMENTAL; Interventions: Drug: topical voriconazole / levofloxacin systemic itraconazole | Arm Label: conventional treatment +CXL; Type: ACTIVE_COMPARATOR; Interventions: Drug: topical voriconazole / levofloxacin systemic itraconazole, Radiation: CXL | Intervention Type: DRUG; Name: topical voriconazole / levofloxacin systemic itraconazole; Assigned to Arm(s): conventional treatment, conventional treatment +CXL | Intervention Type: RADIATION; Name: CXL; Assigned to Arm(s): conventional treatment +CXL
B: Arm Label: 30 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin, Device: UVX Light | Arm Label: 45 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Device: UVX Light | Intervention Type: DRUG; Name: riboflavin; Assigned to Arm(s): 30 minute light duration | Intervention Type: DEVICE; Name: UVX Light; Assigned to Arm(s): 30 minute light duration, 45 minute light duration
C: Arm Label: Accelerated Corneal Cross-linking; Type: EXPERIMENTAL; Interventions: Procedure: Accelerated Corneal Cross-linking | Arm Label: Sham Accelerated Corneal Cross-linking; Type: SHAM_COMPARATOR; Interventions: Procedure: Accelerated Corneal Cross-linking | Intervention Type: PROCEDURE; Name: Accelerated Corneal Cross-linking; Assigned to Arm(s): Accelerated Corneal Cross-linking, Sham Accelerated Corneal Cross-linking
D: Arm Label: Active Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Riboflavin, Drug: Dextran, Device: UVA Light Source | Arm Label: Control Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Drug: Dextran | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Active Treatment Arm, Control Treatment Arm | Intervention Type: DRUG; Name: Dextran; Assigned to Arm(s): Active Treatment Arm, Control Treatment Arm | Intervention Type: DEVICE; Name: UVA Light Source; Assigned to Arm(s): Active Treatment Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ICU Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder Following Critical Illness
Brief Summary: The incidence of PTSD post ICU varies from unit to unit, however a significant number of patients have been shown to develop this disorder. Many patients do not recall their stay in ICU properly and yet can clearly recall nightmares, hallucinations or paranoid delusions, which may be very frightening for the patient to recall at a later stage. As yet, no interventional studies have had an impact on the development of PTSD in this population of patients. However, a recent observational multi-centre study suggested that those patients receiving a diary of their time in ICU had lower levels of symptoms of PTSD than those who did not. These results need to be verified in the form of a randomized study.


Options:
A: N/A
B: Arm Label: Coping skills training; Type: EXPERIMENTAL; Interventions: Behavioral: coping skills training | Arm Label: education program; Type: ACTIVE_COMPARATOR; Interventions: Other: education program | Intervention Type: BEHAVIORAL; Name: coping skills training; Assigned to Arm(s): Coping skills training | Intervention Type: OTHER; Name: education program; Assigned to Arm(s): education program
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Standardized Followup program; Type: EXPERIMENTAL; Interventions: Other: Standardized Followup program | Intervention Type: OTHER; Name: Standardized Followup program; Assigned to Arm(s): Standardized Followup program
D: Arm Label: Discussion with nurse; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ICU Diary; Type: EXPERIMENTAL; Interventions: Other: ICU Diary | Intervention Type: OTHER; Name: ICU Diary; Assigned to Arm(s): ICU Diary

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients
Brief Summary: Patients requiring hemodialysis following kidney failure need a form of dialysis vascular access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an enormous clinical problem. While the best form of vascular access is the arteriovenous fistula (AVF), its primary problem is early, aggressive cellular ingrowth that leads to poor maturation of the vessel, preventing its use for dialysis. Strategies to prevent AVF failure are needed.

Vitamin D is a hormone present in all human bodies and is important for good bone formation and immune function. There is new information that links vitamin D to the function of our veins and arteries, which are used in the creation of an arteriovenous fistulae. Our bodies can make vitamin D and can also get vitamin D from our diet. However, a majority of patients with chronic kidney disease and end-stage renal disease (ESRD) have low vitamin D levels (vitamin D deficiency). There are several benefits to correcting low vitamin D levels, however, it is not know whether correcting low vitamin D in the body will lead to better function of the vein and artery used for arteriovenous fistulae creation. The main goal of this pilot study is to examine the role of vitamin D supplementation on AVF maturation and useability for dialysis. Study results will be used to develop larger studies to examine the specific effect that vitamin D supplementation has on the vessels used for AVF creation and whether vitamin D promotes AVF maturation.


Options:
A: Arm Label: GTN patch; Type: EXPERIMENTAL; Interventions: Drug: GTN patch | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo comparator | Intervention Type: DRUG; Name: GTN patch; Assigned to Arm(s): GTN patch | Intervention Type: DRUG; Name: placebo comparator; Assigned to Arm(s): Placebo patch
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
D: Arm Label: AV fistula with VasQ; Type: EXPERIMENTAL; Interventions: Device: VasQ | Arm Label: AV fistula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: VasQ; Assigned to Arm(s): AV fistula with VasQ

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation
Brief Summary: The purpose of this study is to develop and test a text messaging-based smoking cessation program for adults who are currently smoking and want to quit, living in Turkey.


Options:
A: Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Standard Care + Text message; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message | Arm Label: Standard Care + Text Message + ABT; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message, Behavioral: Adherence Behavioral Therapy | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Standard Care, Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Adherence Behavioral Therapy; Assigned to Arm(s): Standard Care + Text Message + ABT
B: Arm Label: SMS Turkey; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Turkey | Arm Label: Brochure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS Turkey; Assigned to Arm(s): SMS Turkey
C: Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: text messaging for smoking cessation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic text messages | Intervention Type: BEHAVIORAL; Name: text messaging for smoking cessation; Assigned to Arm(s): Text Messaging | Intervention Type: BEHAVIORAL; Name: Generic text messages; Assigned to Arm(s): Control
D: Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Arm Label: Cell phone Aplication for Smarth Phone; Type: ACTIVE_COMPARATOR; Interventions: Device: Cell phone Aplication for Smarth Phone | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group | Intervention Type: DEVICE; Name: Cell phone Aplication for Smarth Phone; Assigned to Arm(s): Cell phone Aplication for Smarth Phone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation
Brief Summary: The purpose of this study is to develop and test a text messaging-based smoking cessation program for adults who are currently smoking and want to quit, living in Turkey.


Options:
A: Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: text messaging for smoking cessation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic text messages | Intervention Type: BEHAVIORAL; Name: text messaging for smoking cessation; Assigned to Arm(s): Text Messaging | Intervention Type: BEHAVIORAL; Name: Generic text messages; Assigned to Arm(s): Control
B: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tabac Info Service | Arm Label: Current practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tabac Info Service; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: SMS Turkey; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Turkey | Arm Label: Brochure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS Turkey; Assigned to Arm(s): SMS Turkey
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: HAR, Behavioral: AWARD, Other: Referral card, Other: A4 leaflet | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: LTM, Behavioral: AWARD, Other: Referral card, Other: A4 leaflet | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice, Other: 12-page booklet | Intervention Type: BEHAVIORAL; Name: HAR; Assigned to Arm(s): Group A | Intervention Type: BEHAVIORAL; Name: LTM; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: AWARD; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: Referral card; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: A4 leaflet; Assigned to Arm(s): Group A, Group B | Intervention Type: BEHAVIORAL; Name: Brief advice; Assigned to Arm(s): Group C | Intervention Type: OTHER; Name: 12-page booklet; Assigned to Arm(s): Group C

Answer: C